TD Cowen raised the firm’s price target on Travere Therapeutics (TVTX) to $60 from $45 and keeps a Buy rating on the shares. The firm said Travere delivered a solid Q1, with $105MM US Filspari sales despite seasonal headwinds.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVTX:
- Travere Therapeutics price target raised to $55 from $53 at Wedbush
- Travere Therapeutics price target raised to $59 from $53 at Citi
- Travere Therapeutics price target raised to $57 from $47 at H.C. Wainwright
- Travere Therapeutics Bets Big on FILSPARI Momentum
- Travere Therapeutics reports Q1 EPS 5c, consensus (5c)